Search | Clinical Trials Finder

Conditions: Pompe Disease (Infantile-Onset), Glycogen Storage Disease Type II (GSD II), Glycogenosis 2, Acid Maltase Deficiency
Interventions: alglucosidase alfa; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Up to 12 Months
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 14
States / cities: Little Rock, Arkansas • Oakland, California • Gainsville, Florida + 11 more

Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 370
States / cities: Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more

Conditions: Immune Thrombocytopenia
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 10 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 13 more

Conditions: Ulcerative Colitis (UC)
Interventions: Adalimumab, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 42
States / cities: Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more

Conditions: Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions: Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 67
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more

Conditions: HIV Infections
Interventions: Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1996
U.S. locations: 3
States / cities: St Louis, Missouri • Rochester, New York • Seattle, Washington

Conditions: Pain
Interventions: morphine sulfate extended release capsules; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years and older
Enrollment: 1,570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 378
States / cities: Adamsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 314 more

Conditions: Mild Cognitive Impairment, Dementia
Interventions: Resources and Activities for Life Long Independence (RALLI), Social Walking program (SW); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 70 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Colorectal Neoplasms
Interventions: Tepotinib, Cetuximab; Drug · Biological
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more

Conditions: Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions: clinical observation, infrared photocoagulation therapy; Other · Device
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 27 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Cystic Fibrosis
Interventions: Home lung function and symptom monitoring; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Carotid Artery Disease
Interventions: Carotid WALLSTENT Monorail Endoprosthesis, FilterWire EZ™ System™; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,097 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 112
States / cities: Birmingham, Alabama • Fairhope, Alabama • Phoenix, Arizona + 94 more

Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage III Major Salivary Gland Carcinoma, Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Interventions: Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat; Other · Biological · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acromegaly
Interventions: Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Irritable Bowel Syndrome
Interventions: DDP733; Drug
Lead sponsor: Dynogen Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 62
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 53 more

Conditions: Narcolepsy With Cataplexy
Interventions: Xyrem; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 17
States / cities: Long Beach, California • Orange, California • Redwood City, California + 14 more

Conditions: Pregnancy Related, Cannabis Use
Interventions: Dronabinol; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Investigators choice of SoC, AAA817; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 27
States / cities: Los Angeles, California • Palo Alto, California • Santa Barbara, California + 22 more

Conditions: Multiple Myeloma
Interventions: ACY-1215, lenalidomide, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 5
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more

Conditions: Back Pain
Interventions: TransDiscal System, Medical Management; Device · Other
Lead sponsor: Halyard Health; Industry
Eligibility: 21 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Orlando, Florida • Bloomington, Illinois + 6 more

Conditions: Opioid-use Disorder
Interventions: Mindful Awareness in Body-oriented Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Bellingham, Washington • Port Angeles, Washington • Seattle, Washington

Conditions: Cervical Cancer
Interventions: Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 38
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more

Conditions: Acute Coronary Syndrome
Interventions: Dalcetrapib, Placebo; Drug
Lead sponsor: DalCor Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 186
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more

Conditions: Non-Small Cell Lung Cancer
Interventions: INC280 single agent, erlotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Detroit, Michigan + 2 more

Search by objective public record fields.

A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza

Exercise and Activities for Independent Living With Mild Cognitive Impairment (MCI)

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Early Intervention in Cystic Fibrosis Exacerbation

A Carotid Stenting Boston Scientific Surveillance Program

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females

A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy

Effects of Pregnancy-associated Hormones on THC Metabolism in Women

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Safety and Efficacy of the TransDiscal System Versus Medical Management in Treating Chronic Discogenic Low Back Pain

Mindful Body Awareness With Medication Treatment for Opioid Use Disorder

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification